DDInter776 DDInter1376
Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Formoterol {u} (Compound) resembles {v} (Compound) Fenoterol
Formoterol {u} may lead to a major life threatening interaction when taken with {v} Labetalol
Formoterol {u} (Compound) resembles {v} (Compound) Arbutamine
Formoterol {u} (Compound) treats {v} (Disease) chronic obstructive pulmonary disease
Formoterol {u} (Compound) binds {v} (Gene) ADRB1
Formoterol {u} (Compound) upregulates {v} (Gene) HMOX1
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Formoterol {u} (Compound) downregulates {v} (Gene) RPS4Y1
Formoterol {u} (Compound) causes {v} (Side Effect) Anxiety
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Formoterol (Compound) resembles Fenoterol (Compound)
Formoterol may lead to a major life threatening interaction when taken with Labetalol
Formoterol (Compound) resembles Arbutamine (Compound)
Formoterol (Compound) treats chronic obstructive pulmonary disease (Disease)
Formoterol (Compound) binds ADRB1 (Gene)
Formoterol (Compound) upregulates HMOX1 (Gene)
Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Formoterol (Compound) downregulates RPS4Y1 (Gene)
Formoterol (Compound) causes Anxiety (Side Effect)